Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

WHO Clinical Trial Finds New Ebola Vaccine Gives 100 Percent Protec

red-cross-ebolaWashington, DC, December 26, 2016 — Donald G. McNeil Jr. reports that, in a scientific triumph that will change the way the world fights a terrifying killer, an experimental Ebola vaccine tested on humans in the waning days of the West African epidemic has been shown to provide 100 percent protection against the lethal disease.

The vaccine has not yet been approved by any regulatory authority, but it is considered so effective that an emergency stockpile of 300,000 doses has already been created for use should an outbreak flare up again.

Since Ebola was discovered in the former Zaire in 1976, there have been many efforts to create a vaccine.

All began with a sense of urgency but then petered out for lack of money.  Although only about 1,600 people died of Ebola over those years, the grotesque nature their deaths — copious hemorrhaging from every orifice — has lent the disease a frightening reputation.

Ultimately, only the huge, explosive 2014 outbreak that took 11,000 lives in Africa and spread overseas, killing a handful of people in Europe and the United States, provided the political and economic drive to make an effective vaccine.

The Ebola trial was led by the World Health Organization, the Guinean Health Ministry, Norway’s Institute of Public Health and other institutions.

The vaccine, known as rVSV-EBOV, was developed over a decade ago by the Public Health Agency of Canada and the United States Army and is now licensed to Merck.

For McNeil’s full story, click here.